Neurofilaments as biomarkers in neurological disorders
M Khalil, CE Teunissen, M Otto, F Piehl… - Nature Reviews …, 2018 - nature.com
Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …
Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis
C Bridel, WN Van Wieringen, H Zetterberg… - JAMA …, 2019 - jamanetwork.com
Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …
number of neurological conditions compared with healthy controls (HC) and is a candidate …
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Objective Neurofilament light chains (NfL) are unique to neuronal cells, are shed to the
cerebrospinal fluid (CSF), and are detectable at low concentrations in peripheral blood …
cerebrospinal fluid (CSF), and are detectable at low concentrations in peripheral blood …
Molecular biomarkers in multiple sclerosis
T Ziemssen, K Akgün, W Brück - Journal of neuroinflammation, 2019 - Springer
Multiple sclerosis (MS) is an inflammatory-neurodegenerative disease of the central nervous
system presenting with significant inter-and intraindividual heterogeneity. However, the …
system presenting with significant inter-and intraindividual heterogeneity. However, the …
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
D Rotstein, X Montalban - Nature Reviews Neurology, 2019 - nature.com
Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …
clinical features, but current knowledge gaps, including validation of biomarkers and …
The “rights” of precision drug development for Alzheimer's disease
There is a high rate of failure in Alzheimer's disease (AD) drug development with 99% of
trials showing no drug-placebo difference. This low rate of success delays new treatments …
trials showing no drug-placebo difference. This low rate of success delays new treatments …
[HTML][HTML] Brain health: time matters in multiple sclerosis
Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
The role of ceramide and sphingosine-1-phosphate in Alzheimer's disease and other neurodegenerative disorders
K Czubowicz, H Jęśko, P Wencel, WJ Lukiw… - Molecular …, 2019 - Springer
Bioactive sphingolipids—ceramide, sphingosine, and their respective 1-phosphates (C1P
and S1P)—are signaling molecules serving as intracellular second messengers. Moreover …
and S1P)—are signaling molecules serving as intracellular second messengers. Moreover …
Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis
J Åkesson, S Hojjati, S Hellberg, J Raffetseder… - Nature …, 2023 - nature.com
Sensitive and reliable protein biomarkers are needed to predict disease trajectory and
personalize treatment strategies for multiple sclerosis (MS). Here, we use the highly …
personalize treatment strategies for multiple sclerosis (MS). Here, we use the highly …
Mitochondrial dysfunction, protein misfolding and neuroinflammation in Parkinson's disease: roads to biomarker discovery
Parkinson's Disease (PD) is a highly prevalent neurodegenerative disease among older
adults. PD neuropathology is marked by the progressive loss of the dopaminergic neurons …
adults. PD neuropathology is marked by the progressive loss of the dopaminergic neurons …